CDKN2A and neoplasm: Since BMI1 is a proto-oncogene capable of inactivating the tumour suppressor Cyclin Dependent Kinase Inhibitor 2 A (CDKN2A)15, it would be reasonably to think that this fusion should contribute to the low levels of CDKN2A that characterize this type of neoplasms.